Translating Research Into Impact
Together we will find treatments and cures for children's genetic diseases
On this page
Strategic Partnership Opportunities
We partner with industry leaders to accelerate breakthrough therapies, transforming discoveries in genetics, gene therapy and cancer research into life-changing treatments for patients worldwide.
Research Partnerships
Advance your R&D pipeline through customised collaboration with our world-leading scientists. We design and execute innovative research projects that align with your therapeutic goals and accelerate development timelines.
Technology Licensing
Access our comprehensive portfolio of patented technologies, including cutting-edge gene therapy platforms, next-generation AAV capsids, advanced cell engineering solutions and early-stage potential cancer therapies to power your therapeutic programs.
World-Class Expertise & Infrastructure
Leverage our deep expertise in vector design, gene editing, vector production and sophisticated in vitro and in vivo models. Our state-of-the-art facilities and experienced teams are ready to accelerate your path to breakthrough treatments.
Partner With Us to Transform Lives
Connect with our Commercialisation Team to explore how our world-class research, resources and intellectual property can accelerate your therapeutic innovations.
Our Impact Through Collaboration
By joining forces with leading research institutes, industry pioneers and healthcare organisations, we're accelerating the development of breakthrough genetic therapies and transforming how we treat childhood genetic diseases.
Novartis (formerly Gyroscope)
Collaboration to design and screen of capsid libraries to identify novel capsids for enhanced delivery of ocular gene therapies.
Tessellate Bio
A spin-out company developing novel precision oncology medicines with the mission to turn cancer patients into cancer survivors.
DiNAQOR
Collaboration to develop novel bioengineered adeno-associated virus (AAV) capsids to route gene therapy directly to human cardiac muscle.
CTNNB1 Foundation
Collaboration to design and screen of capsid libraries to identify novel capsids for enhanced delivery of ocular gene therapies.
Bloomsbury Therapeutics
Patients into cancer survivors. Partnership with a clinical-stage biotechnology company to introduce gene therapy clinical trials for OTC-deficiency.
Alexion, AstraZeneca (formerly LogicBio)
Collaboration to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues.